SPARK-BIH National Gene and Cell Therapies Webinar Lecture Series 2025

Thursday 26th June 3:30-4:30 CET



GCT National Strategy Gene- and Cell-Based Therapies Project Funding

Road to the clinic: how to translate your research into a manufacturing process

Dr. Melissa van Pel

Dr. Melissa van Pel obtained her PhD degree at the University of Utrecht in 2003. After an academic career focusing on molecular, cellular, and functional aspects of hematopoieticand stromal cell populations, Melissa's work shifted towards Cell Therapy product development, process development, product characterisation and clinical manufacturing of Cell Therapies according to cGMP and other international standards.



In 2020, she joined NecstGen as Head of Cell Therapy where she contributed to the design, engineering and set-up of NecstGen. At NecstGen, Melissa is responsible for process development and clinical manufacture of novel Cell and Gene Therapy products.

This session will provide an in-depth analysis of process development. Process development aim is to translate a research-grade process into a GMP compliant manufacture method, which is robust and reproducible despite the donor-to-donor variations. During process development, key decisions should be made on the production process, testing strategy, target product profile and activities can be undertaken to challenge the cost of goods.

In her presentation, Melissa will share her knowledge on process development, clinical manufacture and testing strategies for Cell Therapies.

Online via MS Teams | Please register <u>here</u>!

Registration to the webinar is required in advance in order to receive MS Teams meeting link. The event is hosted by SPARK-BIH at the Berlin Institute of Health at Charité, Berlin, Germany.

This lecture series is part of the Project Funding Program of National Strategy for Gene- and Cell-based Therapies

SPARK is an initiative created at Stanford University to overcome challenges associated with translation of academic discoveries.

